AUCTORES
Globalize your Research
Mini-Review
*Corresponding Author: Tania Leme da Rocha Martinez, Nephrology Department, BP - A Beneficência Portuguesa de São Paulo, São Paulo, Brazil.
Citation: Sidney C Fernandes, Anita L. R. Saldanha, Ana P P Margeotto,André L V Gasparoto, Tania L R Martinez . (2021) First Choice Lipid-Lowering Treatment of Hypercholesterolemias. Journal of Cardiology Research and Reports 3(1): Doi: 10.31579/2692-9759/014
Copyright: © 2021, Tania Leme da Rocha Martinez. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited
Received: 09 February 2021 | Accepted: 15 March 2021 | Published: 16 March 2021
Keywords: hypercholesterolemia, statins, pleiotropic actions, HMG-CoA reductase, PCSK9 inhibitors
Several recent studies with lipid-lowering substances have shown a significant reduction in complications of this disease with drastic reduction of LDL-cholesterol levels. However, a huge proportion of patients in secondary prevention remain with inefficient treatment. Vastatins, also called statins, are considered worldwide as the first-line pharmacotherapy for the treatment of hypercholesterolemia, being the most efficient drugs to lower LDL-cholesterol, still presenting excellent tolerability. The main mechanism of action of vastatins is inhibition of the enzyme hydroxymethylglutaril-coenzyme A (HMG-CoA) reductase. Currently, the therapeutic arsenal for cases of family hypercholesterolemia and statin intolerance incorporated PCSK9 inhibitors (proprotein convertase subtilisin/kexin type 9) which is an enzyme that is involved in the degradation of the LDL- cholesterol receptor in the lysosome, preventing its recycling to the cell surface, thus reducing the amount of LDL- cholesterol receptors available, with consequent elevation of this lipid. Mutations with gain of function that lead to an increase in the expression of this enzyme cause, therefore, an increase in LDL- cholesterol, while mutations that lead to a decrease in its expression decrease LDL-cholesterol.
Several recent studies [1-6] with lipid-lowering substances have shown a significant reduction in complications of this disease with drastic reduction of low density lipoprotein cholesterol (LDL-C) levels. However, a huge proportion of patients in secondary prevention remain with inefficient treatment. [7, 8]
Pharmacological treatment of dyslipidemias is indicated primarily for patients at medium and high risk for atherosclerosis and acute pancreatitis. The higher the patient's risk, the greater the benefit with the use of lipid-lowering substances. The treatment should be permanent and the longer the time of use of the drug, the greater the benefit achieved.
In addition, some points should be checked before the beginning of drug treatment: whether all preparation and planning of the case were complete; whether the goals of LDL-C and other lipid parameters were calculated; if dyslipidemia is not secondary (e.g., hypothyroidism, kidney disease, liver disease, drug use, alcoholism); whether dietary treatment and lifestyle changes (lifestyle change, with recommendation for physical activity, smoking cessation and alcoholism when applicable) have already been implemented and whether the selection of the drug is ideal for the treatment of dyslipidemia and cardiovascular risk (or pancreatitis) for the patient in question.
The indication for the use of lipid-lowering substances is set out in Chart 1. [9].
LDL-C = Low Density Lipoprotein. *At medical discretion, based on studies such as HPS, [9] PROVE-IT TIMI 22 [1] REVERSAL, [2] TNT, [3] ASTEROID [5] (it is suggested here to discuss with the patient the advantages and disadvantages of using pharmacotherapy for joint decision-making).
The following will be discussed the various types of substances available for the treatment of dyslipidemias.
Vastatins: also called statins, are considered worldwide as the first-line pharmacotherapy for the treatment of hypercholesterolemia, being the most efficient drugs to lower LDL-C, still presenting excellent tolerability. According to Roberts, [10] vastatins are for atherosclerosis just as penicillin is for infectious diseases. These substances reduce the risk of death, myocardial infarction, need for myocardial revascularization and ischemic stroke around 30%, as shown by the MRC/BHF studies, [11] 4S, [12] CARE, [13] LIPID, [14] WOSCOPS, [15] AFCAPS/TexCAPS, [16] ASCOT-LLA, [17] LIPS,[18] CARDS,[19] MIRACL, [20] JUPITER, [6] and also slow progression or even lead to regression of atherosclerotic disease, as shown in REVERSAL [1] and ASTEROID studies [5].
It is important to note that this benefit occurred in secondary prevention studies with high cholesterol (4S), with low cholesterol (LIPID); borderline values (CARE); with in-normal cholesterol and with patients with values considered even low (HPS); primary prevention with high values (WOSCOPS); (AFCAPS/TexCAPS); in the primary prevention group for cardiovascular events in hypertensive patients (ASCOT) and diabetics (CARDS); patients with stabilized coronary disease (4S, CARE) or acute ischemic syndrome (MIRACL).
Mechanism of action: The main mechanism of action of vastatins is inhibition of the enzyme hydroxymethylglutaril-coenzyme A (HMG-CoA) reductase. This enzyme is responsible for catalyzing the reaction that transforms HMG-CoA into mevalonate, a reaction that is the limiting factor of cholesterol synthesis.
Inhibition of this reaction leads to a decrease in cholesterol synthesis, with an increase in the expression of LDL hepatic receptors, which leads to a more pronounced removal of LDL lipoprotein particles from plasma. The induction of the LDL receptor gene occurs by the action of SREBP (steroid responsive element binding-protein), one of the peptides responsible for intracellular cholesterol homeostasis [21].
Vastatins also lead to a decrease in triglycerides that is more modest than cholesterol, being more evident when there is hypertriglyceridemia above 250 mg/dl. The mechanism for this effect may be by an increase in the removal of very low density lipoprotein (VLDL) from plasma by the greater expression of LDL receptors or even by a decreased hepatic production of VLDL by the liver. [22]
In addition to decreasing triglycerides, the reduction of the hepatic synthesis of VLDL also leads to a drop in LDL-C, which is independent of the increase in LDL receptor expression, as shown by the study by Raal et al., [23] in which, in 35 patients with homozygous family hypercholesterolemia, atorvastatin at a dose of 80 mg/day led to a decrease in LDL-C by 28%, and of these patients, 30 had a residual activity of the LDL receptor; however, 5 were negative receptors and obtained the same reduction rate, and this reduction was obtained with the reduction of VLDL synthesis (and, consequently, LDL).
Effectiveness: All vastatins produce a significant reduction in LDL-C (between 18 and 58%), with a more slight decrease in triglycerides (between 7 and 30%) and a small increase in HDL-C (between 5 and 15%).
Chart 2 shows the effect of several vastatins on different dosages on the decrease in LDL-C.
It is observed that the least potent vastatine is fluvastatin and the most potent, rosuvastatin. It is also verified that, when doubling the dose of vastatin, the reducing effect of LDL-C increases by only 6% on average, and this fact is an important limiting factor to achieve the LDL-C goals recommended by the current guidelines.
There is also a great variation in the response to the effect of vastatins, which may be due to genetic or environmental factors.
Among the genetic factors that affect the response to vastatin, what has received greater attention is the ApoE gene, which can present three isoforms: e2, e3 and e4, and one individual may have six different genotypes: homozygote e2, e3 and e4 or heterozygotes e2/e3, e2/e4 and e3/e4, knowing that the homozygous genotype e2 is the one with the highest response, followed by homozygote e3 and homozygous e4 [24]. On the contrary, homozygous patients e4 respond better to the diet. This seems to occur because carriers of the e4 allelo are better absorbers of dietary cholesterol, with cholesterolemia being less dependent on the cellular synthesis of cholesterol and, therefore, less sensitive to its inhibition.
Among the extrinsic factors that can alter the response to vastatins, the main ones are:
Adherence to diet
- Administration hours, being recommended its use in the evening after dinner, due to the circadian rhythm of activity of HMG-CoA reductase, which is more active at night
- Ingestion of foods containing fibers, mainly pectin and oat meal, together with vastatins can lead to a decrease in their absorption [25].
- Concomitant administration of other drugs, especially those that are metabolized by cytochrome P450 3A4. In this regard, substances that induce this enzymatic system (carbamazepine, diphenyl-hyantoin, rifampicin) decrease the effect of lovastatin, sinvastatin and atorvastatin, while inhibitory substances of this system (cyclosporine, amiodarone, diltiazem) increase the concentration of these drugs and consequently their effect. Pravastatin, fluvastatin and rosvastatin, which do not have their metabolism dependent on cytochrome P450 3A4, no longer suffer as much interference from drugs that alter this system.
Pleiotropic effects: in addition to the effects that improve the lipid profile, vastatins have important antiatherosclerotic vascular effects, with improvement of endothelial function, decrease in the load of atheroma determined by intravascular ultrasound and also anti-inflammatory and immunomodulatory effects, which lead to reduced morbidity and mortality. However, it is discussed whether these effects are due only to the fact that vastatins reduce LDL-C or if these drugs have other actions independent of it. The mevalonate, in addition to a cholesterol precursor, is also of prenilated proteins, which are part of the cell signaling cascade that affects the proliferation of smooth muscle cells [26, 27] and also of geranilgeranil phosphate and ubiquinone which are important components in several intracellular inflammatory signaling cascades. Therefore, the decrease in the synthesis of these substances, by inhibiting the formation of mevalonate, leads to less efficient inflammatory cell signaling, resulting in decreased inflammatory cytokines.
It is also observed that vastatins, in addition to reducing LDL-C, have other lipid effects: they increase absorption by endocytosis, degradation and prevent LDL oxidation, decrease LDL accumulation in macrophages, interfere in lipoprotein secretion and increase the expression of SRB1 receptors, important in reverse cholesterol transport.
It was also verified that vastatins selectively inhibit leukocyte function antigen-1 [28] LFA-1 (also called aL-b2 or CD11a/CD18), a heterodum that belongs to the family of b2 integrin and is involved in lymphocytic recirculation, leukocyte scans at inflammation sites and activation of T cells by antigen-presenting cells. This effect is independent of the inhibition of HMG-CoA reductase and occurs by chemical binding of vastatins in an alllosteric site within LFA-1, causing inhibition of the receptor. This property of vastatins has been explored in studies for the treatment of psoriasis, rheumatoid arthritis, ischemia/reperfusion injury and transplant rejection.
Perhaps related to this inhibition and/or also to the interference in the formation of geranilgeranil phosphate and ubiquinone, is the effect related to the decrease in transplant vasculopathy and the increase in survival that is observed with the use of vastatins in transplanted patients.
Regarding cognitive function, there does seem to actually be a link between hypercholesterolemia and Alzheimer's disease. Some studies show the protective effect of vastatins, but not other lipid-lowering factors, in the prevention of cognitive dysfunction [29, 30].
Still very debatable and awaiting the results of studies, is the effect of vastatins on the improvement in osteoporosis and faster consolidation of bone fractures.
Regarding the action of vastatins on bone metabolism, all recent data available in the literature suggest a positive effect of these drugs on bone mass, through 2 types of effects: inhibition of reabsorption and stimulation of bone formation (anti-resorption and anabolic effects). Therefore, in the near future, vastatins may appear among the substances used in the prevention and treatment of osteoporosis, mainly due to the current familiarity of clinicians with their use [31].
A beneficial effect of vastatin has also been shown to prevent thromboembolism and thromboembolic phenomena.32 In this study, which randomized healthy men and women, the use of rosvastatin was also demonstrated, the use of rosvastatin was associated with a 36% reduction in the risk of thromboembolism, an effect that appears to be an independent benefit from the use of this vastatin, in addition to reducing the risk of arterial thrombosis. Expanding the treatment objective to include thromboembolism prevention and death, in addition to arterial thrombosis, significantly increases the estimated benefit of the use of vastatins.
Safety and tolerability: vastatins are substances that have an excellent safety profile, with a very low incidence of side effects, the most important being hepatotoxicity and myopathy.
Asymptomatic changes in hepatic transaminases occur in 2 to 5% of patients using vastatins, are temporary, reversible with drug suspension and do not lead to liver failure or permanent liver injury. It is recommended to discontinuation of the drug if transaminases exceed 3 times the higher normal values.
Myopathy accompanied by increased creatinephosphokinase (CPK) rarely occurs (0.1%), as well as with rhabdomyolysis. Drugs (e.g., cyclosporine, antifungals, amiodarone, genfibrozil), hypothyroidism and women with low weight are associated with a higher incidence of myopathy and liver alterations, and these particular cases should be monitored with greater care.
Patients using vastatins should be instructed to immediately report symptoms of fatigue, muscle pain or weakness, fever, dark urine, or any other symptom that appears shortly after the introduction of the drug or increased dosage, as side effects grow at higher doses.
Other side effects include epigastric pain or burning, abdominal pain, diarrhea, constipation, flatulence, headache, and urticariform or allergic skin lesions. These effects are rarely important to the point of leading to discontinuation of treatment.
The JUPITER [6] study showed a 28% increase in the incidence of diabetes mellitus in patients who used rosuvastatin. Further analysis of this study [33] found, however, that the benefits of reducing cardiovascular events and mortality associated with the use of rosuvastatin exceeded the risk of diabetes; it also showed that patients who developed diabetes were at increased risk for the development of this disease.
No study has shown an association with the use of vastatins with a high incidence of any type of cancer, anxiety, depression or other psychological changes.
Dosage: As has already been said, the synthesis of cholesterol is higher at night and in the early hours of the morning. Vastatins should therefore be administered after dinner or at bedtime. It should start with a small dose, which should be increased until lipid targets can be achieved. If a significant reduction in LDL-C (50%) is intended, it should be initiated with a more potent vastatin (e.g., atorvastatin, rosuvastatin or, as will be shown below, with an association). If a smaller reduction is desired, something around 20 to 30%, one can start with any other vastatin. For the minimum and maximum doses, see Chart 3.
Contraindications: vastatins are contraindicated in active liver disease, pregnancy and lactation, and in women of childbearing age, unless an efficient contraceptive method is used. They should also be suspended in conditions that may lead to renal failure due to rhabdomyolysis, such as septicemia, hypotension, major surgeries, polytraumatized patients, etc.
In summary, vastatins are the drugs of choice for the treatment of hypercholesterolemia. Its use, in general, is permanent. They should be administered daily after dinner.
To achieve a reduction in LDL-C for high-risk patients at levels recommended by the current guidelines, with a decrease of about 50% of baseline LDL-C, atorvastatin at a dose of 80 mg/day and rosuvastatin at a dose of 20 mg/day are more efficient. Vastatins can also be used in conjunction with drugs that have a different mechanism of action to obtain a synergism of action.
Contemporarily - Several drugs that are approved for clinical use. The following stand out:
PCSK9 inhibitors: PCSK9 (proprotein convertase subtilisin/kexin type 9) is an enzyme that is involved in the degradation of the LDL-C receptor in the lysosome, preventing its recycling to the cell surface, thus reducing the amount of LDL-C receptors available, with consequent elevation of this lipid. Mutations with function gain that lead to an increase in the expression of this enzyme therefore cause an increase in LDL-C, while mutations that lead to a decrease in its expression decrease LDL-C [34, 35]. Antibodies against this protein have been developed and are already in phase 3 studies of investigation, and release is expected for clinical use soon.
Mipomersen: is an oligonucleotide inhibitor of ApoB synthesis. To date, clinical studies with more than 800 patients have been researched, with four phase 3 randomized, double-blind, placebo-controlled studies involving approximately 400 patients. Mipomersen is rapidly absorbed after subcutaneous administration, has an average half-life of about 30 days. It is metabolized by the enzyme class of nucleases, with renal excretion of its metabolites. It is efficient in reducing all particles containing ApoB and can be used alone or in combination with other lipid-lowering substances, especially vastatins, obtaining a synergistic effect [36, 37, 38].
Berberine: used in China for decades to treat diarrhea, is studied as a reduction of LDL-C, acting with increased expression of LDL receptor by a post-transcriptional mechanism. There are no clinical studies yet.
Apoprotein A-1 (Apo A1) mimetic peptides: they are a-helix peptides that form complexes with phospholipids, considered synthetic ApoA that, when injected, behave like the original ApoA, increasing HDL.
None.
Abbreviations
Apo A-1: Apoprotein A-1
HMG-CoA: hydroxymethylglutaril-coenzyme A
LDL-C: low density lipoprotein cholesterol
VLDL: very low density lipoprotein
Conflicts of interest: No conflict of interest.
Clearly Auctoresonline and particularly Psychology and Mental Health Care Journal is dedicated to improving health care services for individuals and populations. The editorial boards' ability to efficiently recognize and share the global importance of health literacy with a variety of stakeholders. Auctoresonline publishing platform can be used to facilitate of optimal client-based services and should be added to health care professionals' repertoire of evidence-based health care resources.
Journal of Clinical Cardiology and Cardiovascular Intervention The submission and review process was adequate. However I think that the publication total value should have been enlightened in early fases. Thank you for all.
Journal of Women Health Care and Issues By the present mail, I want to say thank to you and tour colleagues for facilitating my published article. Specially thank you for the peer review process, support from the editorial office. I appreciate positively the quality of your journal.
Journal of Clinical Research and Reports I would be very delighted to submit my testimonial regarding the reviewer board and the editorial office. The reviewer board were accurate and helpful regarding any modifications for my manuscript. And the editorial office were very helpful and supportive in contacting and monitoring with any update and offering help. It was my pleasure to contribute with your promising Journal and I am looking forward for more collaboration.
We would like to thank the Journal of Thoracic Disease and Cardiothoracic Surgery because of the services they provided us for our articles. The peer-review process was done in a very excellent time manner, and the opinions of the reviewers helped us to improve our manuscript further. The editorial office had an outstanding correspondence with us and guided us in many ways. During a hard time of the pandemic that is affecting every one of us tremendously, the editorial office helped us make everything easier for publishing scientific work. Hope for a more scientific relationship with your Journal.
The peer-review process which consisted high quality queries on the paper. I did answer six reviewers’ questions and comments before the paper was accepted. The support from the editorial office is excellent.
Journal of Neuroscience and Neurological Surgery. I had the experience of publishing a research article recently. The whole process was simple from submission to publication. The reviewers made specific and valuable recommendations and corrections that improved the quality of my publication. I strongly recommend this Journal.
Dr. Katarzyna Byczkowska My testimonial covering: "The peer review process is quick and effective. The support from the editorial office is very professional and friendly. Quality of the Clinical Cardiology and Cardiovascular Interventions is scientific and publishes ground-breaking research on cardiology that is useful for other professionals in the field.
Thank you most sincerely, with regard to the support you have given in relation to the reviewing process and the processing of my article entitled "Large Cell Neuroendocrine Carcinoma of The Prostate Gland: A Review and Update" for publication in your esteemed Journal, Journal of Cancer Research and Cellular Therapeutics". The editorial team has been very supportive.
Testimony of Journal of Clinical Otorhinolaryngology: work with your Reviews has been a educational and constructive experience. The editorial office were very helpful and supportive. It was a pleasure to contribute to your Journal.
Dr. Bernard Terkimbi Utoo, I am happy to publish my scientific work in Journal of Women Health Care and Issues (JWHCI). The manuscript submission was seamless and peer review process was top notch. I was amazed that 4 reviewers worked on the manuscript which made it a highly technical, standard and excellent quality paper. I appreciate the format and consideration for the APC as well as the speed of publication. It is my pleasure to continue with this scientific relationship with the esteem JWHCI.
This is an acknowledgment for peer reviewers, editorial board of Journal of Clinical Research and Reports. They show a lot of consideration for us as publishers for our research article “Evaluation of the different factors associated with side effects of COVID-19 vaccination on medical students, Mutah university, Al-Karak, Jordan”, in a very professional and easy way. This journal is one of outstanding medical journal.
Dear Hao Jiang, to Journal of Nutrition and Food Processing We greatly appreciate the efficient, professional and rapid processing of our paper by your team. If there is anything else we should do, please do not hesitate to let us know. On behalf of my co-authors, we would like to express our great appreciation to editor and reviewers.
As an author who has recently published in the journal "Brain and Neurological Disorders". I am delighted to provide a testimonial on the peer review process, editorial office support, and the overall quality of the journal. The peer review process at Brain and Neurological Disorders is rigorous and meticulous, ensuring that only high-quality, evidence-based research is published. The reviewers are experts in their fields, and their comments and suggestions were constructive and helped improve the quality of my manuscript. The review process was timely and efficient, with clear communication from the editorial office at each stage. The support from the editorial office was exceptional throughout the entire process. The editorial staff was responsive, professional, and always willing to help. They provided valuable guidance on formatting, structure, and ethical considerations, making the submission process seamless. Moreover, they kept me informed about the status of my manuscript and provided timely updates, which made the process less stressful. The journal Brain and Neurological Disorders is of the highest quality, with a strong focus on publishing cutting-edge research in the field of neurology. The articles published in this journal are well-researched, rigorously peer-reviewed, and written by experts in the field. The journal maintains high standards, ensuring that readers are provided with the most up-to-date and reliable information on brain and neurological disorders. In conclusion, I had a wonderful experience publishing in Brain and Neurological Disorders. The peer review process was thorough, the editorial office provided exceptional support, and the journal's quality is second to none. I would highly recommend this journal to any researcher working in the field of neurology and brain disorders.
Dear Agrippa Hilda, Journal of Neuroscience and Neurological Surgery, Editorial Coordinator, I trust this message finds you well. I want to extend my appreciation for considering my article for publication in your esteemed journal. I am pleased to provide a testimonial regarding the peer review process and the support received from your editorial office. The peer review process for my paper was carried out in a highly professional and thorough manner. The feedback and comments provided by the authors were constructive and very useful in improving the quality of the manuscript. This rigorous assessment process undoubtedly contributes to the high standards maintained by your journal.
International Journal of Clinical Case Reports and Reviews. I strongly recommend to consider submitting your work to this high-quality journal. The support and availability of the Editorial staff is outstanding and the review process was both efficient and rigorous.
Thank you very much for publishing my Research Article titled “Comparing Treatment Outcome Of Allergic Rhinitis Patients After Using Fluticasone Nasal Spray And Nasal Douching" in the Journal of Clinical Otorhinolaryngology. As Medical Professionals we are immensely benefited from study of various informative Articles and Papers published in this high quality Journal. I look forward to enriching my knowledge by regular study of the Journal and contribute my future work in the field of ENT through the Journal for use by the medical fraternity. The support from the Editorial office was excellent and very prompt. I also welcome the comments received from the readers of my Research Article.
Dear Erica Kelsey, Editorial Coordinator of Cancer Research and Cellular Therapeutics Our team is very satisfied with the processing of our paper by your journal. That was fast, efficient, rigorous, but without unnecessary complications. We appreciated the very short time between the submission of the paper and its publication on line on your site.
I am very glad to say that the peer review process is very successful and fast and support from the Editorial Office. Therefore, I would like to continue our scientific relationship for a long time. And I especially thank you for your kindly attention towards my article. Have a good day!
"We recently published an article entitled “Influence of beta-Cyclodextrins upon the Degradation of Carbofuran Derivatives under Alkaline Conditions" in the Journal of “Pesticides and Biofertilizers” to show that the cyclodextrins protect the carbamates increasing their half-life time in the presence of basic conditions This will be very helpful to understand carbofuran behaviour in the analytical, agro-environmental and food areas. We greatly appreciated the interaction with the editor and the editorial team; we were particularly well accompanied during the course of the revision process, since all various steps towards publication were short and without delay".
I would like to express my gratitude towards you process of article review and submission. I found this to be very fair and expedient. Your follow up has been excellent. I have many publications in national and international journal and your process has been one of the best so far. Keep up the great work.
We are grateful for this opportunity to provide a glowing recommendation to the Journal of Psychiatry and Psychotherapy. We found that the editorial team were very supportive, helpful, kept us abreast of timelines and over all very professional in nature. The peer review process was rigorous, efficient and constructive that really enhanced our article submission. The experience with this journal remains one of our best ever and we look forward to providing future submissions in the near future.
I am very pleased to serve as EBM of the journal, I hope many years of my experience in stem cells can help the journal from one way or another. As we know, stem cells hold great potential for regenerative medicine, which are mostly used to promote the repair response of diseased, dysfunctional or injured tissue using stem cells or their derivatives. I think Stem Cell Research and Therapeutics International is a great platform to publish and share the understanding towards the biology and translational or clinical application of stem cells.
I would like to give my testimony in the support I have got by the peer review process and to support the editorial office where they were of asset to support young author like me to be encouraged to publish their work in your respected journal and globalize and share knowledge across the globe. I really give my great gratitude to your journal and the peer review including the editorial office.
I am delighted to publish our manuscript entitled "A Perspective on Cocaine Induced Stroke - Its Mechanisms and Management" in the Journal of Neuroscience and Neurological Surgery. The peer review process, support from the editorial office, and quality of the journal are excellent. The manuscripts published are of high quality and of excellent scientific value. I recommend this journal very much to colleagues.
Dr.Tania Muñoz, My experience as researcher and author of a review article in The Journal Clinical Cardiology and Interventions has been very enriching and stimulating. The editorial team is excellent, performs its work with absolute responsibility and delivery. They are proactive, dynamic and receptive to all proposals. Supporting at all times the vast universe of authors who choose them as an option for publication. The team of review specialists, members of the editorial board, are brilliant professionals, with remarkable performance in medical research and scientific methodology. Together they form a frontline team that consolidates the JCCI as a magnificent option for the publication and review of high-level medical articles and broad collective interest. I am honored to be able to share my review article and open to receive all your comments.
“The peer review process of JPMHC is quick and effective. Authors are benefited by good and professional reviewers with huge experience in the field of psychology and mental health. The support from the editorial office is very professional. People to contact to are friendly and happy to help and assist any query authors might have. Quality of the Journal is scientific and publishes ground-breaking research on mental health that is useful for other professionals in the field”.
Dear editorial department: On behalf of our team, I hereby certify the reliability and superiority of the International Journal of Clinical Case Reports and Reviews in the peer review process, editorial support, and journal quality. Firstly, the peer review process of the International Journal of Clinical Case Reports and Reviews is rigorous, fair, transparent, fast, and of high quality. The editorial department invites experts from relevant fields as anonymous reviewers to review all submitted manuscripts. These experts have rich academic backgrounds and experience, and can accurately evaluate the academic quality, originality, and suitability of manuscripts. The editorial department is committed to ensuring the rigor of the peer review process, while also making every effort to ensure a fast review cycle to meet the needs of authors and the academic community. Secondly, the editorial team of the International Journal of Clinical Case Reports and Reviews is composed of a group of senior scholars and professionals with rich experience and professional knowledge in related fields. The editorial department is committed to assisting authors in improving their manuscripts, ensuring their academic accuracy, clarity, and completeness. Editors actively collaborate with authors, providing useful suggestions and feedback to promote the improvement and development of the manuscript. We believe that the support of the editorial department is one of the key factors in ensuring the quality of the journal. Finally, the International Journal of Clinical Case Reports and Reviews is renowned for its high- quality articles and strict academic standards. The editorial department is committed to publishing innovative and academically valuable research results to promote the development and progress of related fields. The International Journal of Clinical Case Reports and Reviews is reasonably priced and ensures excellent service and quality ratio, allowing authors to obtain high-level academic publishing opportunities in an affordable manner. I hereby solemnly declare that the International Journal of Clinical Case Reports and Reviews has a high level of credibility and superiority in terms of peer review process, editorial support, reasonable fees, and journal quality. Sincerely, Rui Tao.
Clinical Cardiology and Cardiovascular Interventions I testity the covering of the peer review process, support from the editorial office, and quality of the journal.
Clinical Cardiology and Cardiovascular Interventions, we deeply appreciate the interest shown in our work and its publication. It has been a true pleasure to collaborate with you. The peer review process, as well as the support provided by the editorial office, have been exceptional, and the quality of the journal is very high, which was a determining factor in our decision to publish with you.
The peer reviewers process is quick and effective, the supports from editorial office is excellent, the quality of journal is high. I would like to collabroate with Internatioanl journal of Clinical Case Reports and Reviews journal clinically in the future time.
Clinical Cardiology and Cardiovascular Interventions, I would like to express my sincerest gratitude for the trust placed in our team for the publication in your journal. It has been a true pleasure to collaborate with you on this project. I am pleased to inform you that both the peer review process and the attention from the editorial coordination have been excellent. Your team has worked with dedication and professionalism to ensure that your publication meets the highest standards of quality. We are confident that this collaboration will result in mutual success, and we are eager to see the fruits of this shared effort.
Dear Dr. Jessica Magne, Editorial Coordinator 0f Clinical Cardiology and Cardiovascular Interventions, I hope this message finds you well. I want to express my utmost gratitude for your excellent work and for the dedication and speed in the publication process of my article titled "Navigating Innovation: Qualitative Insights on Using Technology for Health Education in Acute Coronary Syndrome Patients." I am very satisfied with the peer review process, the support from the editorial office, and the quality of the journal. I hope we can maintain our scientific relationship in the long term.
Dear Monica Gissare, - Editorial Coordinator of Nutrition and Food Processing. ¨My testimony with you is truly professional, with a positive response regarding the follow-up of the article and its review, you took into account my qualities and the importance of the topic¨.
Dear Dr. Jessica Magne, Editorial Coordinator 0f Clinical Cardiology and Cardiovascular Interventions, The review process for the article “The Handling of Anti-aggregants and Anticoagulants in the Oncologic Heart Patient Submitted to Surgery” was extremely rigorous and detailed. From the initial submission to the final acceptance, the editorial team at the “Journal of Clinical Cardiology and Cardiovascular Interventions” demonstrated a high level of professionalism and dedication. The reviewers provided constructive and detailed feedback, which was essential for improving the quality of our work. Communication was always clear and efficient, ensuring that all our questions were promptly addressed. The quality of the “Journal of Clinical Cardiology and Cardiovascular Interventions” is undeniable. It is a peer-reviewed, open-access publication dedicated exclusively to disseminating high-quality research in the field of clinical cardiology and cardiovascular interventions. The journal's impact factor is currently under evaluation, and it is indexed in reputable databases, which further reinforces its credibility and relevance in the scientific field. I highly recommend this journal to researchers looking for a reputable platform to publish their studies.
Dear Editorial Coordinator of the Journal of Nutrition and Food Processing! "I would like to thank the Journal of Nutrition and Food Processing for including and publishing my article. The peer review process was very quick, movement and precise. The Editorial Board has done an extremely conscientious job with much help, valuable comments and advices. I find the journal very valuable from a professional point of view, thank you very much for allowing me to be part of it and I would like to participate in the future!”
Dealing with The Journal of Neurology and Neurological Surgery was very smooth and comprehensive. The office staff took time to address my needs and the response from editors and the office was prompt and fair. I certainly hope to publish with this journal again.Their professionalism is apparent and more than satisfactory. Susan Weiner
My Testimonial Covering as fellowing: Lin-Show Chin. The peer reviewers process is quick and effective, the supports from editorial office is excellent, the quality of journal is high. I would like to collabroate with Internatioanl journal of Clinical Case Reports and Reviews.
My experience publishing in Psychology and Mental Health Care was exceptional. The peer review process was rigorous and constructive, with reviewers providing valuable insights that helped enhance the quality of our work. The editorial team was highly supportive and responsive, making the submission process smooth and efficient. The journal's commitment to high standards and academic rigor makes it a respected platform for quality research. I am grateful for the opportunity to publish in such a reputable journal.
My experience publishing in International Journal of Clinical Case Reports and Reviews was exceptional. I Come forth to Provide a Testimonial Covering the Peer Review Process and the editorial office for the Professional and Impartial Evaluation of the Manuscript.
